에노테쿠맵

Enoticumab
에노테쿠맵
단클론 항체
유형전항체
출처인간
대상DLL4
임상자료
기타 이름REGN421
ATC 코드
  • 없는
식별자
CAS 번호
켐스파이더
  • 없는
유니
케그

에노테쿠맵(REGN421, INN)은 DLL4에 결합하는 인간 단핵항체다.면역억제제 역할을 한다.[1][2][3][4][5]

참조

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK (June 2016). "Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth". Mol. Cancer Ther. 15 (6): 1344–52. doi:10.1158/1535-7163.MCT-15-0144. PMC 4893925. PMID 27009216.
  3. ^ Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G (October 2015). "Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer". Cancer Res. 75 (19): 4086–96. doi:10.1158/0008-5472.CAN-14-3773. PMID 26377940.
  4. ^ Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A (June 2015). "A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors". Clin. Cancer Res. 21 (12): 2695–703. doi:10.1158/1078-0432.CCR-14-2797. PMID 25724527.
  5. ^ Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R (2014). "Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts". PLOS ONE. 9 (11): e112371. Bibcode:2014PLoSO...9k2371M. doi:10.1371/journal.pone.0112371. PMC 4231048. PMID 25393540.


Stub icon

이 단핵 항체 관련 기사는 단조롭다.위키피디아를 확장하여 도울 수 있다.